Home
overview

Building on almost two decades worth of expertise in fighting the growing threat of antimicrobial resistance (AMR), SMi Group are thrilled to announce the return of Superbugs and Superdrugs USA which arrives to Iselin, New Jersey on November 13th & 14th 2017.

Antimicrobial resistance has sparked an urgency in the development of new drugs as the industry strives for novel solutions to fight infectious diseases. Innovation and collaboration is requested at every level making Superbugs & Superdrugs USA, the perfect platform to strengthen knowledge in key principles such as funding incentives and global strategy, whilst honing in on clinical developments in areas such as immunotherapy, toxoid based vaccines and anti-body drug conjugates.

As methods move away from traditional small molecule antibiotics, this is critical time for AMR experts, government bodies and industry leaders, to come together and share ideas on the latest developments in treatment and prevention.

.

 Previous Attendee Testimonials:

"Very enjoyable and informative meeting" - Micromyx
"Great meeting to network and have time to discuss face to face. Key questions and issues.
Very collaborative open meeting." - ROCHE
"Good conference" - MHRA
"I am particularly excited to hear the sessions that will be led by John Rex" - BARDA
"It’s always good to be cognizant of new science and potential opportunities" - Janssen
"I’m particularly looking forward to the session on public/private partnerships" - Pfizer
 

  • Guidelines for successfully seeking funding and partnership with updates on the CARB-X initiative
  • Understand the importance of supporting natural immunity and the microbiome for reducing infection from resistant bacteria
  • New insight into developments for treating gram-negative infections
  • Explore the emerging and non-traditional approaches to antimicrobial drug development, including biologic drugs and combination treatment

 

CEOs, Chiefs, VPs, Directors, Heads, Principals of:

  • Antibacterial
  • Infectious Disease
  • R&D
  • Microbiology

or working in the area of superbugs and superdrugs from pharmaceutical, biotech and research organizations!
 

Past attendees include:

ABAC Therapeutics; Achaogen; Achaogen Inc; Albany College of Pharmacy and Health Sciences - Vermont Campus; Allecra Therapeutics; Appili Therapeutics; AstraZeneca; BARDA; Blueberry Therapeutics Ltd. ; Bugworks Research India; ContraFect; CUBRC, Org; Destiny Pharma Ltd; Elanco Animal Health; Entasis Therapeutics; Evince Biosciences; HBMS; Hutchison Biofilm Medical Solutions; Ian Davidson LLC; Janssen Research & Development, LLC; JSC R-PHARM; Latham Biopharm Group; Merck, Mail Stop K-15-F 370; Micromyx LLC; Modern Medical PC; Morton Findlay Associates Ltd; Motif BioSciences; N8 Medical LLC; National Institute Of Allergy And Infectious Diseases; NATO/ SACT HQ; NeoSome Life Sciences, LLC; NIAID; Noigel, LLC; Pan American Health Organization (PAHO); Pfizer Antibacterials RU; PHARMA OMNIUM; Phico Therapeutics Ltd; Polyphor Ltd; Sanderling Consulting LLC; Seventure Partners; Shionogi Inc; Shionogi inc.; Spero Therapeutics; University of North Texas Health Science Center; Venaticus AB; Venaticus Symcel ; Versant Ventures; Zoetis;

Conference programme

8:30 Registration & Coffee

8:50 Chairs' Opening Remarks

William Weiss

William Weiss, Director, UNT Health Science Center

Simon Lynch

Simon Lynch, Senior Scientific Director, Janssen Fellow & Incubator Leader, Janssen Research & Development, LLC

9:10 Challenges and opportunities in antibacterial development

Mark Albrecht

Mark Albrecht, Project Officer, HHS/ASPR/BARDA

• Why BARDA is interested in antimicrobial resistance (AMR)
• How BARDA is addressing the issue of AMR
• Stimulating innovation in antimicrobial research and development

9:50 Innate defense regulators: Broad-spectrum, host-directed therapy for antibiotic resistant disease

Oreola Donini

Oreola Donini, Chief Scientific Officer, Soligenix, Inc.

• Innate immunity is a host-directed approach for treatment of infectious disease, equally capable of treatment antibiotic sensitive and antibiotic resistant organisms
• Preclinical studies demonstrated an ability to combat infection while modulating inflammation and enhancing tissue healing
• Clinically, the lead clinical IDR, dusquetide, has been demonstrated to be safe and efficacious in Phase 1 and 2 studies
• In a Phase 2 study, dusquetide reduced the duration of severe oral mucositis in head and neck cancer patients receiving chemoradiation therapy, while also decreasing the incidence of bacterial infections

10:30 Morning Coffee

11:00 Funding, filing, and finance

• What’s up with funding initiatives: CARB-X update
• Advances in regulatory tools: Tier C makes headway
• Paying for it all: Evolving global discussions of payor models

John  Rex

John Rex, Chief Medical Officer , F2G Ltd

11:40 Iclaprim, a novel diaminopyrimidine, for the treatment of serious Gram-positive infections

Rajesh Shukla

Rajesh Shukla, Vice President Clinical Operations, Motif bio

• Iclaprim addresses an unmet medical need in hospitalized patients with serious and life threatening infections including MRSA
• Iclaprim possesses a differentiated product profile in target patient populations
• provides a near-term product opportunity
 

12:20 Networking Lunch

13:30 Pathways & Policies to Facilitate Antibiotic Development

Nicole           Mahoney

Nicole Mahoney, Director, Global Regulatory Policy, Merck

Antibiotic resistance continues to be a focus for policy makers determined to ensure the continued availability of effective treatments for patients with serious infections. This talk will provide an update on recent discussions with an emphasis on policy developments and an exploration of ways to assess the value of these critical treatments.

• Update on pathways to study priority antibiotics
• New opportunities to assess the societal value of antibiotics                
• Highlights from recent policy discussions and recommendations to spur innovation
 

14:10 Immunity and antibodies versus multi-drug resistant bacteria

Ken Stover

Ken Stover, Senior Director, Microbial Sciences, MedImmune

• Multi-mechanistic antibodies and their potential for serious bacterial infections
• Pathogen-specific prophylaxis and treatment and antibody synergy with antibiotic therapy
• Challenges for a paradigm shift away from reliance on broad spectrum antibiotics

14:50 Forging ahead with a new class of antibiotics

Zachary Zimmerman

Zachary Zimmerman, CEO, Forge Therapeutics, Inc.

• Novel metal-binding chemistry & process to rationally design effective metalloenzyme inhibitors
• Small molecules that inhibit LpxC with broad spectrum against drug resistant Gram-negative bacteria
• IV & oral efficacy in animal infection models
• Advancing preclinical development through collaborations and non-dilutive funding
 

15:30 Afternoon Tea

16:00 PANEL DISCUSSION: New funding opportunities – lessons learned

• What are the options for companies developing antimicrobials?
• The main challenges in securing funding
• How are regulatory bodies like the FDA are supporting the development of antimicrobials and can this be improved?
 

Dmitri Iarikov

Dmitri Iarikov, Deputy Director, Division of Anti-Infective Products, FDA

Mark Albrecht

Mark Albrecht, Project Officer, HHS/ASPR/BARDA

William Weiss

William Weiss, Director, UNT Health Science Center

Simon Lynch

Simon Lynch, Senior Scientific Director, Janssen Fellow & Incubator Leader, Janssen Research & Development, LLC

Zachary Zimmerman

Zachary Zimmerman, CEO, Forge Therapeutics, Inc.

16:40 Targeting Pseudomonas aeruginosa with an antibody-drug conjugate

Obadiah Plante

Obadiah Plante, Director of Research , Visterra

• Conserved target on the bacterial surface of P. aeruginosa
• Considerations in the design of an ADC
• ADCs as a treatment for P. aeruginosa infection

17:20 Targeted lysin therapeutics for serious bacterial infections; bench to bedside

Cara Cassino

Cara Cassino, Chief Medical Officer, ContraFect

• What are phage-derived lysins and how can their novel mechanism of action potentiate conventional antibiotics?
• What do animal models tell us about the potential for lysins to treat serious, biofilm dependent infections?
• What is the therapeutic potential of lysins to combat antimicrobial resistance and improve clinical outcomes?

18:00 Chairs' Closing Remarks and Close of Day One

William Weiss

William Weiss, Director, UNT Health Science Center

Simon Lynch

Simon Lynch, Senior Scientific Director, Janssen Fellow & Incubator Leader, Janssen Research & Development, LLC

8:30 Registration & Coffee

8:50 Chairs' Opening Remarks

William Weiss

William Weiss, Director, UNT Health Science Center

Simon Lynch

Simon Lynch, Senior Scientific Director, Janssen Fellow & Incubator Leader, Janssen Research & Development, LLC

9:10 Navigating the pitfalls of early drug discovery – lessons learned

Karen Joy Shaw

Karen Joy Shaw, Chief Scientific Officer, Amplyx Pharmaceuticals, Inc

• Targets and target product profiles
• Getting the mechanism of action right
• Resistance considerations
• Prospects for new agents

9:50 A new antibiotic class?

Christopher McMaster

Christopher McMaster, President and CEO, DeNovaMed Inc

• De novo computer aided drug design versus a novel target was used to develop a new antibiotic class
• 652 novel molecules were synthesized with over 20 having clinically relevant broad specificity Gram positive efficacy in vitro
• Efficacy in animal models of infection and preclinical PK/ADME point to potential clinical utility
• Thoughts on moving this antibiotic class into Gram negative bacteria will be discussed

10:30 Morning Coffee

11:00 The medical device approach to preventing hospital acquired infections and development of superbugs

Carl Genberg

Carl Genberg, CEO, N8 Medical LLC

• 1.7 million Hospital acquired infections occur annually, 70% of which are related to the use of indwelling medical devices. These add billions to annual health care costs
• The endotracheal tube is a common breeding ground for MDR strains. Polymicrobial biofilm allows horizontal gene transfer and development of new MDR strains. Overuse of antibiotics also allows development of fungal pathogens such as Candida auris
• Patients at high risk of infection are usually immune-compromised; elderly, neonates, diabetics, cancer patients
• The use of innate immune mimic synthetic molecule to coat ETTs and other medical devices prevents bacterial and fungal colonization and growth of biofilms, reducing HAIs and development of superbugs

11:40 The Gram-negative challenge: An early discovery perspective

Ryan Cirz

Ryan Cirz, Director of Early Research, Achaogen Inc

• The scope of the challenge
• Re-tracing the past 15 years of successes and failures
• First-principal challenges in discovery of new chemical classes
• First-principal challenges in the discovery of new modes of action

12:20 Networking Lunch

13:30 Supporting the microbiome to reduce infection by resistant bacteria

Olga Danilchanka

Olga Danilchanka, Microbiome Lead, Merck & Co.

• Patients with a disrupted microbiome (in response to antibiotics) are more vulnerable to infection from resistant bacteria strains
• Slowing antibiotic resistance by minimising the microbiome’s disruption in response to antibacterial treatments

14:10 Evaluating immunotherapeutics as alternatives to antibiotics to treat Gram-negative infections

Mike  Westby

Mike Westby, Director, Centauri Therapeutics

• Targeting specific pathogens
• Recruiting natural immunity
• Preclinical challenges
• Next steps

14:50 Afternoon Tea

15:20 Advances towards preventing Clostridium difficile infections through vaccination

Michael  Pride

Michael Pride, Senior Director Vaccine Immunology, Serology and Diagnostic Assays, Pfizer

• Clostridium difficile is a significant unmet medical need and classified by the CDC as an urgent public health threat.
• Pfizer’s C. difficile toxoid vaccine developed with innovative and proprietary technology.
• Pfizer’s C difficile vaccine candidate protects hamsters from C difficile challenge.
• Phase 1 study demonstrated that Pfizer’s C difficile toxoid vaccine candidate was safe and immunogenic in humans
• Pfizer’s C difficile vaccine is currently in Phase III clinical study. 
 

16:00 Repositioning an older class of drugs: Development of macrolides for the treatment of serious Gram-negative infections

Richard Alm

Richard Alm, Vice President Biology, Macrolide Pharmaceuticals, Inc.

• Challenges in repositioning a Gram-positive drug to be active against Gram-negative pathogens
• Overcoming the restrictions of natural product semi-synthesis to increase compound diversity
• Identifying and addressing any pre-existing pool of resistance in target pathogens

16:40 Multiple strategies to address the problem of MDR Gram-negative pathogens

Timothy Opperman

Timothy Opperman, Senior Scientist, Microbiotix Inc

• Overview of three discovery projects illustrating different approaches to tackling the problem of Gram-negative pathogens
• Virulence.  A novel series phenoxyacetamide series exhibits potent activity against type 3 secretion in Pseudomonas aeruginosa (IC50s as low as 20 nM) by targeting the assembled needle protein PscF, and have demonstrated proof-of-principle efficacy in murine infection models.  This project is funded by CARB-X
• Intrinsic resistance.  Novel pyranopyridine inhibitors of RND-type efflux pump inhibitors exhibit broad spectrum activity against pathogens of the Enterobacteriaceae, favourable pharmacokinetics in mice, and efficacy in a murine infection model
• Novel essential target.  A series of novel oxadiazoles bind to a unique site on the ribosome, resulting in potent inhibition of the essential non-stop ribosome rescue pathway in Gram-positive and –negative pathogens, including MDR Neisseria gonorrhoeae and Francisella tularensis.  These compounds exhibit potent antibacterial activity, oral bioavailability, and efficacy in murine models of infection
 

17:20 Chairs' Closing Remarks and Close of Day Two

William Weiss

William Weiss, Director, UNT Health Science Center

Simon Lynch

Simon Lynch, Senior Scientific Director, Janssen Fellow & Incubator Leader, Janssen Research & Development, LLC

+

FEATURED SPEAKERS

Ken Stover

Ken Stover

Senior Director, Microbial Sciences, MedImmune
Michael  Pride

Michael Pride

Senior Director Vaccine Immunology, Serology and Diagnostic Assays, Pfizer
Olga Danilchanka

Olga Danilchanka

Microbiome Lead, Merck & Co.
William Weiss

William Weiss

Director, UNT Health Science Center

Cara Cassino

Chief Medical Officer, ContraFect
Cara Cassino

Carl Genberg

CEO, N8 Medical LLC
Carl Genberg

Christopher McMaster

President and CEO, DeNovaMed Inc
Christopher McMaster

Dmitri Iarikov

Deputy Director, Division of Anti-Infective Products, FDA
Dmitri Iarikov

John Rex

Chief Medical Officer , F2G Ltd
John  Rex

Karen Joy Shaw

Chief Scientific Officer, Amplyx Pharmaceuticals, Inc
Karen Joy Shaw

Ken Stover

Senior Director, Microbial Sciences, MedImmune
Ken Stover

Mark Albrecht

Project Officer, HHS/ASPR/BARDA
Mark Albrecht

Michael Pride

Senior Director Vaccine Immunology, Serology and Diagnostic Assays, Pfizer
Michael  Pride

Mike Westby

Director, Centauri Therapeutics
Mike  Westby

Nicole Mahoney

Director, Global Regulatory Policy, Merck
Nicole           Mahoney

Obadiah Plante

Director of Research , Visterra
Obadiah Plante

Olga Danilchanka

Microbiome Lead, Merck & Co.
Olga Danilchanka

Oreola Donini

Chief Scientific Officer, Soligenix, Inc.
Oreola Donini

Rajesh Shukla

Vice President Clinical Operations, Motif bio
Rajesh Shukla

Richard Alm

Vice President Biology, Macrolide Pharmaceuticals, Inc.
Richard Alm

Ryan Cirz

Director of Early Research, Achaogen Inc
Ryan Cirz

Simon Lynch

Senior Scientific Director, Janssen Fellow & Incubator Leader, Janssen Research & Development, LLC
Simon Lynch

Timothy Opperman

Senior Scientist, Microbiotix Inc
Timothy Opperman

William Weiss

Director, UNT Health Science Center
William Weiss

Zachary Zimmerman

CEO, Forge Therapeutics, Inc.
Zachary Zimmerman

Sponsors and Exhibitors

Official Media Partner

Official Online Media Partners

Official Publication

Supporters

VENUE

Renaissance Woodbridge Hotel

515 US Highway 1 South, Iselin, New Jersey, USA

Your simple delights will become memorable moments at Renaissance Woodbridge Hotel. This distinctive hotel in Edison, New Jersey, features 269 modern guest rooms, including 42 suites, and more than 25,000 square feet of flexible meeting space. Our hotel's location is centrally located amidst corporate offices and tourist attraction. Our accommodations stand out from other hotels in Edison, NJ, and provide a sophisticated retreat for families and business travelers alike. Marriott's Plug-in panels and 37-inch LCD HD TVs allow guests simultaneous connectivity to laptops, iPods and DVD players. We are one of the most conveniently situated hotels at the crossroads of U.S. Routes 1 and 9. We are also just five minutes from Woodbridge Center Mall, 15 minutes south of Newark Liberty International Airport (EWR) and less than one mile from the Metropark train station. With our premier location and amenities, our Edison accommodations provide an advantageous travel destination.

HOTEL BOOKING FORM

Q&A Released with Forge Therapeutics

Download

PharmaWeek USA 2017 Attendee List

Download

ATTENDEE LIST FOR SUPERBUGS USA & PHARMA MICRO EAST COAST 2017

Download

An Interview with Soligenix

Download

Interview with Motif Biosciences

Download

An Interview with DeNovaMed

Download

Superbugs USA Past Attendee List

Download

Sponsors and Exhibitors


Merck

Sponsors and Exhibitors
http://www.merck.com

For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.


Soligenix, Inc.

Sponsors and Exhibitors
http://www.soligenix.com

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is unmet medical need, including: 1) a therapeutics segment directed at cutaneous T-cell lymphoma and oral mucositis; and 2) a biodefense segment directed at ricin exposure, acute radiation syndrome and antibiotic resistant infectious disease.

Media Partners


American Pharmaceutical Review

Official Media Partner
http://www.americanpharmaceuticalreview.com

Start receiving your free copy today. American Pharmaceutical Review is a review of the drug pipeline from the late discovery phase through manufacturing. American Pharmaceutical Review prides itself on having the most relevant, unbiased and informative editorial in the industry. You will find that all of our editorial is highly technical and written by government agencies, consultants, academics, and large pharmaceuticals companies. American Pharmaceutical Review covers several key topics that are important to drug production:Separations and purification, Drug Delivery, Biopharmaceutical Processing, Biopharmaceutical Development, Formulation development, Manufacturing, Microbiology, Instrumentation, Spectroscopy


Colorado Bioscience

Official Media Partner
http://www.cobioscience.com/

As champions for life science in our state, Colorado BioScience Association leads expansion policies to advance the industry and accelerate growth. We support a thriving bioscience sector by connecting innovators to funding, infrastructure, research and talent. CBSA fosters bioscience workforce and leadership development through opportunities for networking and professional education.


Global Biodefense

Official Media Partner
http://www.globalbiodefense.com/

Global Biodefense publishes the latest news on vaccine and therapeutics countermeasure development, biosurveillance and detection technologies, food safety and biosecurity, and CBRN incident preparedness and response. Visit our website to access daily news updates, organization profiles, conference listings, and the latest in funding opportunities for advancing biodefense technology.

Media Partners


BioChem Adda

Official Online Media Partners
https://www.biochemadda.com/

BioChem Adda is a Not-just-for-Profit organization which aims to bring out the most reliable and transparent information about everything related to jobs, careers, education, news, articles, and events from the field of BioSciences and Chemistry!

Media Partners


Biomedicines Journal

Official Publication
http://www.mdpi.com/journal/biomedicines

Biomedicines (ISSN 2227-9059) is an open access journal devoted to research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. The aim of Biomedicines is publishing high quality papers that address the challenges in bringing biological agents or novel targeted strategies through identification, developmentand ultimately to clinical use. It is published quarterly online by MDPI with rapid publication. Biomedicines is covered by ESCI (Web of Science) and PubMed.

Media Partners


Pharmacircle

Supporters
http://www.pharmacircle.com

PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….


SciDoc Publishers

Supporters
http://www.scidoc.org

SciDoc Publishers is a major source provider of e-journals in the field of Science, Technology and Medicine (STM). The nature of journals - Open Access and Peer-reviewed. We are aimed with a sole motive in making a mark in the field of Open Access, by propagating the knowledge to the scientific community. Our prime concern involves, the knowledge to reach millions of readers and give them access to scientific publications - online.


Swiss Biotech Association

Supporters
http://www.swissbiotech.org/

The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.


Inderscience Publishers

Supporters
http://www.inderscience.com

Inderscience is a dynamic, leading, independent journal publisher. The company disseminates the latest research across the broad fields of science, engineering and technology; management, public and business administration; environment, ecological economics and sustainable development; computing, ICT and internet/web services, and related areas. Inderscience offers over 35 years' experience in publishing and has succeeded in building a substantial collection approaching 400 high-quality peer-reviewed international research journals in both online and print formats. We offer a variety of ways to keep up-to-date with the latest published leading-edge research while our online collection represents a fully-searchable digital archive of around 60,000 articles.


Drug Development Technology

Supporters
http://www.drugdevelopment-technology.com

Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.


PharmaVOICE

Supporters
http://www.pharmavoice.com

PharmaVOICE magazine, and its supporting VIEW publications, provide commentary about the challenges and trends impacting the life-sciences industry, covering a range of issues from molecule through market. PharmaVOICE's more than 41,000 U.S.-based subscribers are also kept abreast of the latest trends through additional media resources, including WebSeminars, Podcasts, Videocasts, and White Papers.


Biosave

Supporters
http://www.Biosave.com

Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.


Pharmaceutical Outsourcing

Supporters
http://www.pharmoutsourcing.com

Pharmaceutical Outsourcing, the journal dedicated to pharmaceutical and biopharmaceutical contract services. With regular sections on contract manufacturing, contract research, contract packaging, formulation/development services, contract analytical testing, APIs, stability testing, clinical research and other areas, we bring the most complete coverage of trends and issues in the industry to our 15,000 readers in North America.


Absave

Supporters
http://www.absave.com

Absave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!


GBI

Supporters
http://www.gbihealth.com/

GBI is an information, applications, and services company focused on the healthcare industry. Leveraging data from across the healthcare value chain, GBI creates web and mobile applications that enable individuals and organizations to make better decisions and communicate more effectively.


SelectScience

Supporters
http://www.selectscience.net/register?utm_source=Media-Partner&utm_medium=Website&utm_campaign=SMI

SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover the latest drug discovery and development technologies, products and techniques with product reviews, videos, application notes and news articles. Become a member for free today.


CanBiotech

Supporters
http://www.canbiotech.com

CanBiotech - A Portal and B2B Outsourcing Marketplace for the Biotech and Pharmaceutical Industry. The Marketplace features the Outsourcing Services Showcase; the Portal features our biopharmaceutical and venture capital directories and databases. Publications include the BioMedical Outsourcing Report and the Bio Outsourcing Asia© Publication.


American Laboratory

Supporters
http://www.americanlaboratory.com

For laboratory managers and researchers utilizing analytical chemistry and its applications, seeking knowledge on new technologies, methods, applications, and products, the American Laboratory® publication platform provides comprehensive technology coverage for laboratory professionals at all stages of their careers. Unlike single-channel publications, American Laboratory® is a multidisciplinary resource that engages scientists through print, digital, mobile, multimedia, and social channels to provide practical information and solutions for cutting-edge results. American Laboratory® serves the need of global community of laboratory professionals for communicating relevant technical advances and insights. Globally, American Laboratory® reaches out to subscribers by offering digital distribution plus premium print in North America. Digital communications utilize internet, mobile and social channels.


Drug Discovery Today

Supporters
http://www.drugdiscoverytoday.com/

Drug Discovery Today is one of the most cited review journals in the field of drug discovery, with an impact factor of 6.422.
Drug Discovery Today will benefit your research by helping to keep you up-to-date with all of the fast-moving and emerging topics in drug discovery. Each issue is packed full of the latest research news, peer-reviewed articles and comment and opinion from leading research scientists.


Gate2Biotech

Supporters
http://www.gate2biotech.com

Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.


Pharmavision

Supporters
http://www.pharmavision.co.uk

PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.


Inderscience Publishers

Supporters
http://www.inderscience.com

Inderscience is a dynamic, leading, independent journal publisher. The company disseminates the latest research across the broad fields of science, engineering and technology; management, public and business administration; environment, ecological economics and sustainable development; computing, ICT and internet/web services, and related areas. Inderscience offers over 35 years' experience in publishing and has succeeded in building a substantial collection approaching 400 high-quality peer-reviewed international research journals in both online and print formats. We offer a variety of ways to keep up-to-date with the latest published leading-edge research while our online collection represents a fully-searchable digital archive of around 60,000 articles.


Rapid Microbiology.com

Supporters
http://www.rapidmicrobiology.com

rapidmicrobiology.com - keep up-to-date with all the latest products for your pharmaceutical microbiology laboratory, subscribe to the rapidmicrobiology.com newsletter http://www.rapidmicrobiology.com/Newsletter.php


Pharmiweb

Supporters
http://www.pharmiweb.com

Established in October 2003, PharmiWeb Solutions is an energetic, innovative provider of web-based solutions for the pharmaceutical sector, with customers such as AstraZeneca, Roche, Servier Laboratories, and Merck With solutions in three key areas: Online Publishing, e-Business and Mobile Computing, we deliver connectivity – between people and applications – unlocking islands of data and knowledge. We own some of the sector’s most innovative Online Publications: PharmiWeb.com, HospitalPharma.com and Detail-Direct.com. We are actively developing solutions for Mobile Computing platforms. For example, our PharmiTabTM e-pharmacy solution runs real-time patient data and prescribing transactions in a busy hospital environment, on a TabletPC, wireless client/server platform. e-Business solutions range from e-Detailing, to Online Market Research, all designed to increase reach, increase sales, and to reduce administration and costs.


Contract Biotechnology

Supporters
http://www.contract-biotechnology.com

Contract-Biotechnology.com is a web-based platform for laboratory outsourcing solutions. We are an online R&D matching tool that connects Scientifics and organizations involved in discovery, development and delivery of new healthcare products with service and products providers worldwide. Life science information technology is undergoing a revolution. Part of that revolution involves new, unexplored business models, open innovation, open data and collaboration. If you have a project or idea that you would like to propose, develop or run, we can help. A New Collaboration Network Model for Discovery Research and Development • Effective Platform: the 95% • 5.000 registered users // > 15.000 Newsletter subscribers • Geographical background: 45,5% Europe / 37,5% North America / 16,5% Asia / 0,5% ROW • Professional background: Outsourcing Manager, Project Manager, CEO, Business Developer, CSO, Account Manager, Sales & Marketing People, Scientists, R&D. For further information, please visit our website www.contract-biotechnology.com


Pharmaceutical Technology

Supporters
http://www.pharmaceutical-technology.com

Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.


Labsave

Supporters
http://www.labsave.com

Labsave is the leading savings website for Laboratory Equipment and Lab Supplies. We work closely with the top suppliers in the world to bring you the best products at the most competitive prices. We are constantly striving to secure the biggest and most exclusive offers that you won’t find anywhere else! http://www.labsave.com/


Technology Networks

Supporters
http://go.technologynetworks.com/subscribe-to-newsletters

Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


Bentham Science

Supporters
http://www.benthamscience.com/

Bentham Science Publishers is a major STM journal publisher of 116 titles and 200 plus open access journals and print/online book series (Bentham eBooks). Bentham Science answers the information needs of the pharmaceutical and biomedical research community. Leading journals include Current Drug Metabolism (Impact Factor 5.113) and Current Medicinal Chemistry (Impact Factor 4.859): FREE online journals and information: www.benthamscience.com


Pharmalicensing

Supporters
http://www.pharmalicensing.com

Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique Partnering Search service and its global network of industry experts to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing, and its sister service Medical Device Licensing (www.medicaldevicelicensingcom) are actively utilized by over 200,000 industry professionals each month. Pharmalicensing is a division of IP Technology Exchange, Inc.

SAVE TO


Outlook Calendar  OUTLOOK CALENDAR
Google Calendar  GOOGLE CALENDAR
ICal Calendar  ICAL CALENDAR
Yahoo! Calendar  YAHOO! CALENDAR

Renaissance Woodbridge Hotel

515 US Highway 1 South
Iselin 08830
USA

Renaissance Woodbridge Hotel

Your simple delights will become memorable moments at Renaissance Woodbridge Hotel. This distinctive hotel in Edison, New Jersey, features 269 modern guest rooms, including 42 suites, and more than 25,000 square feet of flexible meeting space. Our hotel's location is centrally located amidst corporate offices and tourist attraction. Our accommodations stand out from other hotels in Edison, NJ, and provide a sophisticated retreat for families and business travelers alike. Marriott's Plug-in panels and 37-inch LCD HD TVs allow guests simultaneous connectivity to laptops, iPods and DVD players. We are one of the most conveniently situated hotels at the crossroads of U.S. Routes 1 and 9. We are also just five minutes from Woodbridge Center Mall, 15 minutes south of Newark Liberty International Airport (EWR) and less than one mile from the Metropark train station. With our premier location and amenities, our Edison accommodations provide an advantageous travel destination.

HOTEL BOOKING FORM

Title

SubTitle
speaker image

Content


Title


Description

Download


WHAT IS CPD?

CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

CPD AND PROFESSIONAL INSTITUTES

There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

GLOBAL CPD

Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

CPD Certificates

We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

Event Title

Headline

Text
Read More

I would like to speak at an event

I would like to attend an event

I would like to sponsor/exhibit at an event

SIGN UP OR LOGIN

Sign up
Forgotten Password?

Contact SMi GROUP LTD

UK Office
Opening Hours: 9.00 - 17.30 (local time)
SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
Registered in England No: 3779287 VAT No: GB 976 2951 71




Forgotten Password

Please enter the email address you registered with. We will email you a new password.